<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="409">
  <stage>Registered</stage>
  <submitdate>6/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <actrnumber>ACTRN12605000375651</actrnumber>
  <trial_identification>
    <studytitle>Capecitabine and oral cyclophosphamide - a novel oral treatment combination for advanced cancer</studytitle>
    <scientifictitle>Phase I/II study to find the maximum tolerable dose of the combination of capecitabine and oral cyclophosphamide in the treatment of advanced cancer</scientifictitle>
    <utrn />
    <trialacronym>Cyclox I</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral cyclophosphamide days 1-14, plus capecitabine days 1-28 of 28 day treatment cycle.</interventions>
    <comparator />
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Dose limiting toxicities</outcome>
      <timepoint>Assessed over the first 8 weeks of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Steady state plasma levels</outcome>
      <timepoint>Over first 8 weeks of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Develop quality of life questionnaire</outcome>
      <timepoint>Duration of study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Determine efficacy</outcome>
      <timepoint>Best tumour response assessed 8 weekly through out study</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patients are treated until disease progression, unacceptable toxicity or patient/physician decision to withdraw.</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histological / cytological evidence of carcinoma; performance status (WHO) 0-2; adequate bone marrow, renal and hepatic function;recovery from prior chemotherapy toxicity and calculated creatine clearance &gt;50ml/min.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Lack of physical integrity of upper GI tract; more than 2 prior courses of chemotherapy; prior pelvic radiation; pregnant or lactating; investigational drug within 4 weeks; history of clinically significant cardiac disease or MI in past 12 months.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures>This is a phase I study designed to determine the maximum tolerable dose, and recomended phase II dose level of the novel chemotherpy regimen</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>18/07/2000</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Michael Findlay</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Roche International &amp; Roche Products (New Zealand) Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>none</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Michael Findlay</name>
      <address>Cancer Trials New Zealand
Discipline of Oncology
Faculty Medical &amp; Health Sciences
University of Auckland
Private Bag 92019
Auckland</address>
      <phone>+64 9 3737599</phone>
      <fax>+64 9 3737927</fax>
      <email>mp.findlay@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor Michael Findlay</name>
      <address>Cancer Trials New Zealand
Discipline of Oncology
Faculty Medical &amp; Health Sciences
University of Auckland
Private Bag 92019
Auckland</address>
      <phone>+64 9 3737599</phone>
      <fax>+64 9 3737927</fax>
      <email>mp.findlay@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>